Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Larkspur Biosciences

Request full access

Precision immunotherapies targeting cancer cell fitness genes

Cambridge, United StatesFounded 2020Biotech & Life Sciences

About Larkspur Biosciences

Larkspur Biosciences is a biotechnology firm developing precision immunotherapies designed to overcome cancer's ability to evade the immune system. The company was founded in 2020 by world-class scientists Dr. Lewis Cantley, Dr. Nathanael Gray, and Dr. Vijay K. Kuchroo, whose research into cancer cell biology, biochemistry, and immunology forms the company's scientific foundation. Larkspur launched in May 2023 with $35.5 million in a combined seed and Series A financing round led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda Ventures, Inc.

The company’s primary business is the discovery and development of small molecule medicines that target cancer cell fitness genes. This approach aims to make cancer cells more vulnerable to being destroyed by the body's own immune mechanisms. Larkspur's proprietary discovery platform, LarkX, utilizes patient genetics, immune phenotypes, and machine learning to identify new therapeutic targets and predict patient populations most likely to respond to treatment. The business model centers on advancing its pipeline of drug candidates through preclinical and clinical studies, with the ultimate goal of commercializing these therapies or forming strategic partnerships with larger pharmaceutical companies.

Larkspur is advancing several first-in-class programs. Its lead program involves a novel approach to lipid remodeling to make tumors more visible to the immune system. Another key program targets Pin1, a protein involved in fibroblast differentiation, to create a more pro-immune tumor microenvironment. The company is initially focused on a specific subtype of colorectal cancer (CRC) for proof-of-concept studies. Additionally, Larkspur is developing a program targeting the B cell checkpoint TIM-1, based on foundational research from co-founder Dr. Vijay K. Kuchroo, which aims to leverage B cells to enhance anti-tumor responses.

Source: Dealroom company data

At a glance

Status
Operational
Employees
19
Open positions
None listed
Dealroom signal
81.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2023 $25M $99M Takeda Ventures · 3E Bioventures · Polaris Partners · Creacion Ventures ↗
SEED✓Equity / VC Nov 2022 $11M $43M Creacion Ventures · Cornell University · Med-Fine Capital · Polaris Partners ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Larkspur Biosciences website traffic

Latest recorded traffic for Larkspur Biosciences is 910 monthly website visits, down 52.1% over the last three months. Larkspur Biosciences's team grew 5.6% over the past year.

Latest monthly visits910 3-month web change-52.1% 1-year team growth+5.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Larkspur Biosciences in the Cambridge ecosystem

Live from Dealroom

The Larkspur Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Polaris Partners
  • Takeda Ventures
  • 3E Bioventures
  • Creacion Ventures
  • Cornell University
  • Med-Fine Capital

Other known investors1 additional known investor

  • Cornell Tech
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Larkspur Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Larkspur Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.